Skip to main content
LXRX logo

LXRX

Lexicon Pharmaceuticals, Inc.

$2.04

4.62%

Trade Ideas Performance

Latest Closed Trade Idea

$2.04

4.62%
Loading...
We are loading your data. Please wait a moment.

Sentiment

News

0

Social

1

About

Events of Lexicon Pharmaceuticals, Inc. (LXRX)

In the past six months, Lexicon Pharmaceuticals reported a basic EPS loss of $0.04 in Q4 2025, exceeding analysts' estimates. In Q1 2026, the company reported break-even EPS, surpassing analysts' estimates, with revenues soaring to $21.1 million due to a milestone payment from Novo Nordisk. Lexicon announced a $100 million loan facility with Hercules Capital. Positive Phase 2b data for pilavapadin was announced, supporting its advancement to Phase 3. Lexicon received a $10 million milestone payment from Novo Nordisk for LX9851. The stock hit a new 52-week high of $2.00 in May 2026 and has increased by 73.9% since January 1, 2026.

FAQ

Related Assets

Price action provided by Massive. Fundamentals, news and corporate events provided by FactSet. NLP support provided by Perplexity & Gemini. All data is provided for informational purposes only.

Make every trade make sense.

Sign up free. No card required. Three trade ideas a day, the AI analyst, the community - on us.

Get started for FREE (opens in new tab)
Edge Hound mobile app preview on iPhone

Join us and trade with people
who think like you.

The Edge Hound Discord is where serious self-directed investors talk strategy, share setups, and learn from each other. Free to join with any plan - including Free.

Free to join with any plan - including Free.

Join our Discord community (opens in new tab)
Lexicon Pharmaceuticals, Inc. (LXRX) Live Stock Price, Chart & Financial News | Edge Hound